Literature DB >> 15732284

Clinical presentation and monitoring of lupus nephritis.

J E Balow1.   

Abstract

The diversity of clinical presentations of lupus nephritis parallel the diversity of pathologic lesions seen in the kidneys of patients with SLE. Renal manifestations range from asymptomatic hematuria or proteinuria to overt nephritic and nephrotic syndromes, rapidly progressive glomerulonephritis, and chronic renal failure. Subclinical nephropathy both during presentation and during monitoring of disease activity is frequently missed because of the notorious unreliability of routine screening urinalyses performed in high-throughput clinical pathology laboratories. Requisitions for urine microscopy should be flagged for special attention in patients at risk for lupus nephritis. Depression of classic complement pathway components and high titers of anti-DNA, anti-nucleosome, or anti-Clq antibodies identify patients are increased risk of renal involvement or flares of nephritis. Several disease activity and damage indexes are available, but they are mostly used in clinical research setting and none has achieved wide use for standard clinical practice.

Entities:  

Mesh:

Year:  2005        PMID: 15732284     DOI: 10.1191/0961203305lu2055oa

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  25 in total

1.  Monozygotic twins concordant for idiopathic thrombocytopenic purpura and discordant for systemic lupus erythematosus and lupus nephritis.

Authors:  Wen-Chin Huang; Shao-Hung Lien; Deh-Ming Chang; Jang-Jih Lu; Shin-Nang Cheng
Journal:  Eur J Pediatr       Date:  2006-09-15       Impact factor: 3.183

2.  Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes.

Authors:  Q-Z Li; J Zhou; A E Wandstrat; F Carr-Johnson; V Branch; D R Karp; C Mohan; E K Wakeland; N J Olsen
Journal:  Clin Exp Immunol       Date:  2007-01       Impact factor: 4.330

3.  Outcome and predictors of kidney disease progression in Puerto Ricans with systemic lupus erythematosus initially presenting with mild renal involvement.

Authors:  Mariely Nieves-Plaza; Ana P Ortiz; Marilú Colón; María J Molina; Lesliane E Castro-Santana; Vanessa E Rodríguez; Angel M Mayor; Luis M Vilá
Journal:  J Clin Rheumatol       Date:  2011-06       Impact factor: 3.517

Review 4.  Remission and withdrawal of therapy in lupus nephritis.

Authors:  Gabriella Moroni; Francesca Raffiotta; Claudio Ponticelli
Journal:  J Nephrol       Date:  2016-05-04       Impact factor: 3.902

5.  Unravelling the pathogenesis of lupus nephritis: novel genetic study confirms decisive contribution of circulating colony-stimulating factor-1 (CSF-1).

Authors:  Thomas Rauen; Peter R Mertens
Journal:  Int Urol Nephrol       Date:  2010-03-18       Impact factor: 2.370

Review 6.  Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.

Authors:  Paul J Hoover; Karen H Costenbader
Journal:  Kidney Int       Date:  2016-06-22       Impact factor: 10.612

7.  Value of a complete or partial remission in severe lupus nephritis.

Authors:  Yiann E Chen; Stephen M Korbet; Robert S Katz; Melvin M Schwartz; Edmund J Lewis
Journal:  Clin J Am Soc Nephrol       Date:  2007-11-14       Impact factor: 8.237

Review 8.  Recent clinical trials in lupus nephritis.

Authors:  Michael M Ward
Journal:  Rheum Dis Clin North Am       Date:  2014-06-07       Impact factor: 2.670

9.  A prospective study of protein excretion using short-interval timed urine collections in patients with lupus nephritis.

Authors:  Derek M Fine; Martina Ziegenbein; Michelle Petri; Ernest C Han; Alison M McKinley; Jerry W Chellini; Haikady N Nagaraja; Kathryn A Carson; Brad H Rovin
Journal:  Kidney Int       Date:  2009-09-16       Impact factor: 10.612

10.  The role of IL-23/IL-17 axis in lupus nephritis.

Authors:  Zheng Zhang; Vasileios C Kyttaris; George C Tsokos
Journal:  J Immunol       Date:  2009-08-05       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.